For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why ...

Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes. The risk was more modest than ...

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due ...

Patients on semaglutide (Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...

Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Blockbuster GLP-1 medications like Ozempic and Mounjaro might sharpen your figure, but they could also cloud your vision in the process. A review published in JAMA Ophthalmology uncovered at least ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...